Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

NCT02539368 · clinicaltrials.gov ↗

COMPLETED

Status

2565

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn's Disease

Interventions

DRUG: CT-P13
DRUG: Remicade

Sponsor

Pfizer

Collaborators

[object Object]